Day: February 4, 2021

Steve Muehler, the Founder & Senior Managing Member of Private Placement Markets today announced the firm is expanding its new Insurance Brokerage, which is set to begin offering Commercial Insurance Products starting this month, by including Life Insurance and Annuities starting in the Spring of 2021. According to Steve Muehler, “given our vast relationships with many Life Insurance Companies through out the United States through our Commercial Real Estate Financing operations, it only made sense to include Life Insurance and Annuities with out forthcoming Commercial Insurance Products and Services.” Steve Muehler went on to state that, “our research of the market shows that roughly 1 in 5 individuals believe they are under insured with their current life insurance policies. Of that number, more than half visited life insurance company...

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 869,565 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be approximately $260.9 million, excluding any exercise of the underwriters’ option...

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 34,782,609 ordinary shares (or pre-funded warrants in lieu thereof) at a public offering price of $1.15 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter an option for a period of 30 days to purchase up to an additional 5,217,391 ordinary shares on the same terms and conditions. All of the shares (or...

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted...

ALHAMBRA, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline on Wednesday, February 3rd by EMCORE Corporation (Nasdaq: EMKR), please note that the word “revenue” was missing following “combining” in the 3rd paragraph. The corrected release follows:EMCORE Corporation (Nasdaq: EMKR), a leading provider of advanced mixed-signal products that serve the aerospace & defense and broadband communications markets, today announced results for the fiscal 2021 first quarter ended December 31, 2020 (1Q21). Management will host a conference call to discuss financial and business results tomorrow, Thursday, February 4, 2021, at 8:00 AM Eastern Time.Consolidated revenue for 1Q21 was $33.4 million, comprised of $13.6 million from the Aerospace & Defense segment and $19.8 million from the Broadband segment....

BRENTWOOD, Tenn., Feb. 03, 2021 (GLOBE NEWSWIRE) — American Addiction Centers (AAC), a leading provider of substance use services, is going live on Facebook with its new show – “Addiction Talk.” The show interviews celebrities, influencers and everyday people who’ve been impacted by addiction and/or mental health. The show’s goal is to raise awareness about addiction while reducing the stigma often associated with the disease.To watch the first episode and to learn more about the lineup of guests, visit www.americanaddictioncenters.org/social/addiction-talk.“There is nothing more powerful than hearing someone else’s journey and realizing that you are not alone in this fight,” said Stephen Ebbett, AAC’s chief digital and marketing officer. “The idea for the talk show was sparked after a Facebook Live interview we did last year...

New York, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) — Atlas Crest Investment Corp. II (NYSE: ACII.U, the “Company”) announced today that it priced its upsized initial public offering of 30,000,000 units at a price to the public of $10.00 per unit. The units are expected to commence trading on February 4, 2021 on The New York Stock Exchange (the “NYSE”) under the ticker symbol “ACII.U”. Each unit consists of one share of Class A common stock and one-fourth of one warrant, each whole warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be traded on the NYSE under the symbols “ACII” and “ACII.WS,” respectively....

Charlotte, NC, Feb. 03, 2021 (GLOBE NEWSWIRE) — Ballantyne Strong, Inc. (NYSE American: BTN) (“Ballantyne Strong” or the “Company”) today announced the pricing of its underwritten public offering of 3,290,000 shares of its common stock at a public offering price of $2.30 per share, for gross proceeds of $7,567,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company.The offering is expected to close on February 8, 2021, subject to satisfaction of customary closing conditions.ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-238757), including a base prospectus, filed...

GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has executed a binding Heads of Terms agreement with the government of Switzerland to supply six million doses of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, to the country.“The government of Switzerland is working proactively to ensure a sufficient supply of our vaccine that could protect its citizens from COVID-19,” said John J. Trizzino, Chief Commercial Officer and Chief Business Officer of Novavax. “Addressing this global public health crisis requires collaboration, and we appreciate their partnership to provide an urgently needed vaccine to stem the pandemic.”Novavax and Switzerland will negotiate a final...